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INTRODUCTION
The role of chemotherapy has been more impor-
tant in recent multidisciplinary cancer therapy. To
improve the therapeutic effects, a countermeasures
against adverse events and a supportive therapy
become very important. Adverse events in digestive
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Abstract : Supportive therapy during chemotherapy has become essential, but effective
preventive therapies to gastrointestinal mucosal injury are few. We investigated the ef-
ficacy of glutamine in rat anticancer drug-induced enteritis model. In this study, we used
twenty male SD rats. They were divided into control, 5-fluorouracil (5-FU) (orally admin-
istered at 20 mg/kg day), 5-FU+glutamine (1000 mg/kg/day) and 5-FU+glutamine+fiber
and oligosaccharide (GFOR) (1000 mg/kg/day) groups. All groups were sacrificed on day 6
and upper jejunums were excised. The jejunal villous height was measured in specimens.
IgA level in jejunal washing solution, and serum diamine oxidase activity were also meas-
ured. The jejunal villous height was recognized as shorter in the specimen from 5-FU
treated rats compared with 5-FU+glutamine treated rats (p 0.001). Serum diamine oxi-
dase activity in 5-FU+glutamine group were significantly superior to that in 5-FU group
(p=0.028). IgA level in jejunal washing solution tended to be higher in 5-FU+glutamine
group than that in 5-FU group (p=0.076). On the other hand, serum diamine oxidase ac-
tivity and IgA level in jejunal washing solution showed no significant difference between
5-FU+GFO and 5-FU treatment group. Our results suggest that glutamine showed pro-
tective effects on mucosal injury of small intestine in rat anticancer drug-induced enteritis
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system like nausea, vomiting and diarrhea frequent-
ly occur and interrupt the continuation of treatment.
Nausea, vomiting has become controllable due to
the improvement of antiemetic drugs, but effective
preventive therapy is lacking for diarrhea. Atrophy
of the small intestinal mucosa (SIM) might induce
sepsis due to bacterial translocation (BT). In this
pathological condition, declines of not only the intes-
tinal barrier system but also an immune dysfunction
occur. Lymphocytes in the lamina propria mucosa
are important cellular mediators of immunity in SIM.
CD4+ T cells are surrounded by abundant IgA-se-
creting cells, and mainly engaged in humoral immu-
nity (1-4). When the mucosa is injured, the number
and activity of these lymphocytes decrease and ag-
gravate the immune condition.
L-glutamine (glutamine) is an amino acid abun-
dant in the body, and plays an important role, as an
energy source for cells with a fast metabolic turn-
over. Particularly, it has been reported that glutamine
is the major energy substrate of SIM (5).
The preventing effect of glutamine for atrophy of
SIM in an animal enteritis model (6, 7), in animal
parenteral nutrition model (8), and in animal intesti-
nal ischemia-reperfusion injury model (9), has been
reported, but there were no reports concerning the
effects of glutamine for protection of SIM and IgA
secretion in the condition of anticancer drug-in-
duced enteritis. In this study, the preventing effect
of glutamine for atrophy of SIM was investigated
with regard to the histological and immunological
view in rat anticancer drug-induced enteritis model.
MATERIAL AND METHODS
Animals : Seven-week-old male SD rats (Japan
SLC Inc, Hamamatsu, Japan) were used. The ani-
mals were acclimated for 7 days, and given free ac-
cess to food (MF : Oriental Yeast Industry, Tokyo,
Japan) and drinking water. The experiment was per-
formed following the animal management regula-
tions of Tokushima University.
Drugs : 5-FU (Wako Pure Chemical Industries,
Osaka, Japan) was orally administered at 20 mg/
kg/day. The drug was suspended and adjusted to 2
mg/mL with 0.5% hydroxypropyl methyl cellulose
(HPMC : Shinetsu Chemical, Tokyo, Japan) (10).
Supplements : Glutamine (Wako Pure Chemical
Industries, Osaka, Japan) was orally administered at
1,000 mg/kg/day. In addition, GFO (Otsuka Phar-
maceutical, Tokyo, Japan), containing ingredients
such as soluble indigestible dietary fiber and oligo-
saccharides (Table) which was expected to promote
growth of SIM, was administered orally at 1,000
mg/kg/day (200 mg/kg/day as glutamine). Both
supplements were suspended and adjusted to 100
mg/mL with 0.5% HPMC (10). We determined the
dose of glutamine and GFO by reference to the past
report (10) and preliminary experimental results.
Administration of 5-FU and supplements : Twenty
rats were allocated to each of the following 4 groups
(5 rats in each) : Control group, 5-FU group, 5-FU+
glutamine group, 5-FU+GFO group : Glutamine and
GFO were administered to Groups 3 and 4, from 3
days before the study. On day 1-5, 5-FU was admin-
istered to Group 2-4. In addition, glutamine was ad-
ministered to Group 3 and GFO to Group 4, four
hours before 5-FU administration. We adminis-
tered 5-FU and supplements to all rats orally using
dropsonde into the esophagus of rat. All groups
were sacrificed under deep ether anesthesia on
day 6.
MEASUREMENT
① Calorie intake and body weight : During the
study, the dietary calorie intake was measured daily
from day 1 to 5, and the body weight was measured
daily from day 1 to 6.
② IgA level in jejunal washing solution : The jeju-
num was excised for histological examination, and
the lumen was washed with 20 mL of PBS. The IgA
level in the washing solution was measured by
ELISA using a RAT IgA QUANTITATION KIT
(BETHYL Laboratories, INC, Montgomery, USA).
③ Jejunal villous height : The jejunum was fixed
in 10% neutral formalin, and paraffin-embedded,
and 5-μm thin sections were prepared using a mi-
crotome. After being deparaffinized, the sections
were stained with hematoxylin-eosin, and the villi
(μm) in the 10 sections were measured with 100-
times magnification microscope.
④ Serum diamine oxidase (DAO) activity : Blood
Table. Nutritional factors of GFO (15 g)
calorie 36 kcal
protein (glutamine) 3.6 g (3.0 g)
fat 0 g
carbohydrate (lactosucrose) 6.01 g (1.45 g)
dietary fiber 5.0 g
natrium 0.21.2 mg
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(5 ml) was collected from the abdominal aorta. After
standing at room temperature for about 30 minutes,
the blood sample was centrifuged (3,000 rpm at 4
for 15 minutes), and 500 μl of serum was collected.
The samples were stored at -80. The DAO activ-
ity was measured following Takagi’s method (11) :
Cadaverine solution and serum were combined and
heated, followed by the addition of a color former
containing DA-67 and peroxidase, and the activity
was measured by colorimetry at 668 nm using a
spectrophotometer.
STATISTICAL ANALYSIS
Data were expressed MeanSD. For comparison
of the change of calorie intake and body weight,
serum diamine oxidase activity, IgA level in the jeju-
nal washing solution and the jejunal villous height,
Student’s t-test was used. A value of p0.05 was
regarded as a significant.
RESULTS
① Changes in the calorie intake and body weight
The calorie intake was decreased in 5-FU+glu-
tamine group on day 4 and 5 compared to that in
control group. The intake was also decreased in the
5-FU and 5-FU+GFO groups, and the decrease on
day 5 was marked in both groups (Fig. 1). The body
weight continuously increased in control group,
reaching an 8.2% increase on day 6 compared to that
on day 1. In contrast, body weight decreased over
the period in 5-FU group, and the total decrease on
the final day was 11.7%. A 2.8% increase was noted
in 5-FU+glutamine group, but a 5.5% decrease was
noted in 5-FU+GFO group (Fig. 2).
② IgA level in jejunal washing solution
Compared to 21,685.19,059.2 ng/mL in con-
trol group, the IgA level was markedly decreased
(210.348.6 ng/mL) in 5-FU group, suggesting a
marked decline of immunity (p=0.033). The level
was 6,578.35,708.8 ng/mL in 5-FU+glutamine
group, showing a higher level than that in 5-FU
group, but difference was not significant (p=0.150).
In 5-FU+GFO group, the level was 2,280.71,345.6
ng/mL, showing no significant difference from that
in 5-FU group (p=0.870) (Fig. 3).
③ Jejunal villous height
The jejunal villous height was 445.312.9 μm in
control group, whereas it was significantly short-
ened to 223.912.4 μm in 5-FU group (p0.001).
In contrast, the height was 334.619.7 μm in 5-
FU+glutamine group, showing that the villi were
significantly higher than those in 5-FU group (p
0.001). In 5-FU+GFO group, height was 236.34
9.45 μm, showing significant shortening compared
Fig. 1. Calorie intake in each group : The calorie intake de-
creased in 5-FU+glutamine group on day 4 and 5. The calorie in-
take decreased throughout the period in 5-FU and 5-FU+GFO
group.
Fig. 2. Body weight in each group : The body weight decreased
over the period in 5-FU group, and the total decrease on day 6
was 11.7%. A 2.8% increase was noted in 5-FU+glutamine group,
but a 5.5% decrease was noted in 5-FU+GFO group.
Fig. 3. Secretory IgA levels of jejunal washing solution : The
IgA level was markedly decreased in 5-FU group compared to
that in control group. In 5-FU+glutamine group, the level was
higher than that in 5-FU group, but the difference was not sig-
nificant. In 5-FU+GFO group, the level shows no significant dif-
ference from that in 5-FU group.
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to that in 5-FU+glutamine group (p0.001), but sig-
nificantly higher than that in 5-FU group (p=0.027)
(Figs. 4 and 5).
④ Serum DAO activity
Compared to 6.821.6 U/L in control group, the
activity level (3.451.22 U/L) was significantly de-
creased in 5-FU group (p=0.0024). In 5-FU+glu-
tamine group, the activity level was 5.430.65 U/L,
showing a significant inhibition of activity reduc-
tion compared to that in 5-FU group (p=0.0072).
In contrast, no significant inhibition of activity re-
duction (4.021.8 U/L) was noted in 5-FU+GFO
group (p=0.879), showing consistency with the his-
tological findings, respectively (Fig. 6).
DISCUSSION
The purpose of this study was to find effective pre-
venting therapy for anticancer drug induced diar-
rhea. 5-FU was selected as an anticancer drug be-
cause it was very popular effective drug for many
kind of cancers and it has been reported induces in-
testinal mucosal injury in rat model. Enteritis model
was made by administering 5-FU to rats orally at 20
mg/kg once daily for 5 days as reported before (10).
The dietary calorie intake was maintained, and
weight loss was inhibited throughout the period in
5-FU+glutamine group compared to those in 5-FU
group. Histologically, the jejunal mucosal villous
height was maintained, suggesting a protective effect
of glutamine on SIM injury, as previously reported
(6, 7).
We also focused on DAO activity, which is con-
sidered to be an index of SIM condition. DAO is a
polyamine-degrading enzyme localized in the small
intestine and placenta, and controls growth of SIM
in which cell turnovers are very rapid (12, 13). A
correlation between DAO activity levels in small
intestinal tissue and the blood has been reported,
based on which it is considered that the SIM con-
dition can be objectively measured by serum DAO
activity (14). DAO activity was also maintained by
glutamine treatment. Therefore an efficacy of glu-
tamine on anticancer drug-induced enteritis was
suggested .
A total of 200 billion immunocytes are present in
the human small intestine. 60-70% of all peripheral
lymphocytes concentrate in the intestine, therefore
the intestine was called the largest immune organ in
the body (15). The intestinal mucosal immune sys-
tem is roughly divided into gut-associated lymphoid
Fig. 5. Jejunal villous height : The jejunal villous height was
significantly shorter in 5-FU group than those in control group.
In 5-FU+glutamine group, it was significantly higher than those
in 5-FU group. In 5-FU+GFO group, it was shorter than that in
5-FU+glutamine group (data not shown), but higher than that
in 5-FU group.
Fig. 4. Specimens of the jejunal villi (100) : (A)control group :
(B)5-FU group : (C)5-FU+glutamine group : (D)5-FU+GFO
group : Marked atrophy of villi was seen in 5-FU group and 5-
FU+GFO group compared to that in control group. In 5-FU+
glutamine group, the morphology of vill was maintained well com-
pared to that in 5-FU group and 5-FU+GFO group.
Fig. 6. Plasma diamine oxidase (DAO) activity : The plasma
DAO activity level was significantly decreased in 5-FU group com-
pared to that in control group. In 5-FU+glutamine group, it was
significantly higher than that in 5-FU group. In contrast, it showed
no significant difference between 5-FU+GFO group and 5-FU
group.
H. Takechi, et al. Glutamine protects small intestinal mucosa62
tissue, such as Peyer’s patches and mesenteric
lymph nodes, and lymphocytes functioning as cel-
lular mediators of immune system. When antigens
and pathogens are incorporated by Microfold cell in
Peyer’s patch, initiating an immune response, IgA-
positive B cells are formed in the follicular center.
These cells enter the lymph flow and then the sys-
temic circulation through the mesenteric lymph
nodes and thoracic duct, and finally reach the lamina
propria mucosae of the airway, intestine, and vagina.
This pathway is termed “the common mucosal im-
mune system”. The IgA-positive B cells which reach
the lamina propria mucosae through this system are
influenced by IL-4 and IL-5 produced by CD4+ T
cells, differentiated and matured into plasma cells,
and produced IgA, exerting humoral immunity (16,
17). Therefore we measured the IgA level in the
jejunal washing solution from an immunological as-
pect. It was decreased in 5-FU+glutamine group
compared to that in control group, but the decrease
was smaller than that in 5-FU group (p=0.076).
Since glutamine is an energy source for rapidly
growing cells, it may also be used as an energy
source by cancer cells. It should be considered that
cancer cell’s growth might be accelerated by glu-
tamine. In a study using methotrexate-treated rats
that were transplanted fibrosarcoma cells, Klimberg
et al. compared normal diet group and glutamine-
added diet group, and they observed not only the
reduction of the gastrointestinal mucosal disorder,
but also the decreasing of the mortality in glutamine-
added diet group. They concluded that the addi-
tion of glutamine supported the anticancer effect of
methotrexate (10, 18).
Regarding the route of administration, it is appar-
ent that enteral administration is the most efficient
supply route based on the fact that an energy for
chorioepithelial cells actively synthesizing protein
is mostly supplied through the intestine (6, 19-21).
Prebiotics, such as dietary fibers and oligosac-
charides, are fermented by the large intestinal flora,
and short-chain fatty acids are produced. As re-
ported before, these short-chain fatty acids might
increase enteroglucagon secretion from the ileum
and colon, and might promote growth of SIM (22).
We used GFO as a supplement candidate for pro-
moting of SIM, but it did not improve the condition
in 5-FU induced enteritis model. It might be due to
a negative influence of mucosal stimulation by in-
digestible substances. Although GFO was admin-
istered from 3 days earlier than 5-FU administra-
tion, no benefical effects were noted in all rats, and
diarrhea was worsened in some GFO treated rats.
In conclusion, we found glutamine played an im-
portant protective role for anticancer drug-induced
small intestinal mucosa injury in rats by preventing
mucosal atrophy and induced immunity. Glutamine
might also play an important role in clinical practice.
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